AstraZeneca Reports Strong 2025 Financial Results
AstraZeneca announced an 8% increase in total revenue and an 11% rise in core earnings per share for 2025. The company anticipates continued growth in both revenue and earnings for 2026.
Pharmaceutical giant AstraZeneca reported robust financial results for the full year 2025 on February 10, 2026. The company's total revenue grew by 8% to $58.7 billion. This growth was consistent across all major geographic regions and was primarily driven by its oncology, cardiovascular, renal, and respiratory, as well as rare disease portfolios.
AstraZeneca's core earnings per share (EPS) increased by 11% to $9.16. The company also highlighted significant progress in research and development, with 16 positive Phase 3 trial readouts and 43 major regulatory approvals received within the last twelve months. The total dividend declared for fiscal year 2025 was increased by 3% to $3.20 per share.
Further strengthening its global presence, AstraZeneca's ordinary shares began trading on the New York Stock Exchange (NYSE) on February 2, 2026, unifying its listing structure across London, New York, and Stockholm. For the fiscal year 2026, AstraZeneca expects total revenue to increase by a mid-to-high single-digit percentage. Core EPS is projected to grow by a low double-digit percentage.